Background: Arterial stiffness is used as an index of arteriosclerosis. The goal of this study was to clarify whether increased arterial stiffness, evaluated by measuring the brachial-ankle pulse wave velocity (baPWV), is a risk factor for the prognosis of heart failure (HF) patients. Methods and Results: After examination of the baPWV, as well as the levels of neurohumoral factors, the 72 enrolled HF patients were followed up for a survival study, which had a primary endpoint of re-admission because of HF. The secondary endpoint was cardiac death. Results of Cox proportional hazards modeling revealed that baPWV, systolic blood pressure (BP) and brain natriuretic peptide level were factors that affected survival (P<0.05). The patients were divided into 2 groups according to the cutoff baPWV value (1,750 cm/s). Although hemodynamic factors were similar between the groups, the high-baPWV group had a lower event-free survival rate for the primary and secondary endpoints than the low-baPWV group (P<0.05). BP at re-admission was higher in the high-baPWV group (174±30 mmHg) than in the low-baPWV group (121±33 mmHg, P<0.01). Conclusions: Elevated arterial stiffness is a risk factor for re-admission or cardiac death of HF patients. (Circ J 2009; 73: 673 -680) 
rterial stiffness in patients with heart failure (HF) is affected by several factors. First, functional factors, such as hemodynamics, impaired activity of endothelium-derived relaxing factor (nitric oxide) and upregulated neurohumoral factors, can functionally elevate arterial stiffness in HF patients. 1, 2 Second, progression of arteriosclerosis associated with atherosclerosis induces vascular anatomical changes that increase the stiffness of the arterial tree, especially in elderly patients as they age. 3 Therefore, functional and anatomical factors drive arterial stiffness in HF patients.
Pulse wave velocity (PWV) has been used as a gauge of arterial stiffness and applied to several diseases. For instance, elevated arterial stiffness, as evaluated by PWV, is a risk factor for cardiovascular events in patients with hypertension, 4-7 acute coronary syndrome 8 or end-stage renal failure. 9 Similarly, measurement of arterial stiffness in the evaluation of patients with HF has been investigated. A previous study showed that the PWV tended to increase in congestive HF patients as their New York Heart Association (NYHA) functional class advanced. 10 However, reports discussing the prognosis of HF using arterial stiffness measured by PWV are rare; most report on the relationship of arterial stiffness with NYHA class, exercise capacity and left ventricular (LV) function, and the indexes of arterial stiffness used in these previous publications reflect mainly the stiffness of the aorta. The brachial-ankle PWV (baPWV) reflects not only the stiffness of the aorta but also the stiffness of the total arterial tree. Because HF affects the systemic arterial tree, there is a possibility that systemic arterial stiffness affects the prognosis of HF patients. 11 Although increased afterload is known to induce a vicious spiral in acute HF, it is unclear whether elevated arterial stiffness itself is a risk factor for morbidity or mortality in patients with HF. The relationship between elevated arterial stiffness and re-admission because of exacerbation of HF remains to be elucidated.
An equally important question is whether the mechanism of decompensation leading to acute HF can be explained by elevated arterial stiffness. Therefore, in the present study, we tested our hypothesis that elevated arterial stiffness is a prognostic indicator of morbidity and mortality in HF patients.
Accordingly, the first goal of this study was to determine whether elevated arterial stiffness, as evaluated by the baPWV, could be a risk factor for re-admission because of worsening of HF. The second goal was to elucidate the mechanism of decompensation leading to HF in patients with elevated arterial stiffness.
Methods

Study Sample
We enrolled 72 consecutive patients with HF (NYHA II-III). Patients were eligible for inclusion when (1) they had had a history of admission because of HF, as evaluated by the Framingham criteria, 12 and (2) A microphone overlying the left edge of the sternum recorded the heart sounds. ECG leads were attached to both arms for measuring heart rate (HR). The baPWV was calculated using a previously described method. 15 In summary, the time interval (T) between the wave front of the brachial waveform and that of the ankle waveform was measured. The distances between the suprasternal notch and brachial sampling point (Lb) and between the suprasternal notch and ankle sampling point (La) were estimated from the patient's height. The baPWV was then calculated as: baPWV = (La -Lb) / T. Each datum represented the mean value obtained from 10 consecutive pulse waves. The value of baPWV had good reproducibility and correlated well with that of aortic PWV using an invasive method. 15 BP at re-admission was measured with a mercury sphygmomanometer or a digital BP monitor. The BP data from previous admissions for HF was obtained from the medical records.
Blood Sample Measurements
Blood samples were taken to measure the plasma levels of neurohumoral factors: 16 plasma renin activity (PRA), plasma aldosterone concentration (PAC), norepinephrine (NE), brain natriuretic peptide (BNP), C-reactive protein (CRP), total cholesterol (TC) and creatinine. All measurements were performed at an outpatient clinic under steadystate conditions with the patients under their optimized medication.
Statistical Examination and Survival Study
For continuous variables with a normal distribution, data are expressed as the mean ± standard deviation. For variables not normally distributed, the median and interquartile ranges are reported. Comparisons of data between 2 groups were analyzed using Student's t-test. When the distribution of the data was skewed, a nonparametric test (Wilcoxon rank-sum test) was used to analyze the results. For the survival study, the primary endpoint was re-admission because of exacerbation of HF that required more intensive therapy than the usual regimen. We constructed a receiver-operating-characteristic (ROC) curve to analyze baPWV values in order to determine the cutoff points that yielded the highest combined sensitivity and specificity with respect to distinguishing patients with an episode of re-admission for HF from those without such an episode. The secondary endpoint was cardiac death. Patients who had died of non-cardiac causes had their data censored at the time of non-cardiac death. We used univariate Cox proportional hazards analysis to identify variables for the prediction of re-admission. The variables tested were: age, gender, baPWV, BNP, SBP, PP, HR, LVEDd, LVESd, LVEF, left atrial dimension (LAd), TC, creatinine, CRP, PRA, PAC, NE, cause of HF (ischemic or non-ischemic), smoking, diabetes mellitus (DM), and medications. The hazard ratio for BNP was calculated per 100 pg/ml. A value of P<0.05, age, gender, HR and cause of HF were used for the multivariate analysis.
We used multivariate Cox proportional hazards analysis to identify variables for the prediction of re-admission. We used a Cox proportional hazards model to adjust for covariates and to estimate the hazard ratio for re-admission and corresponding 95% confidence interval between groups. Multivariate models were adjusted for baPWV, SBP, BNP, age, gender, HR, PP and cause of HF. Kaplan-Meier curves were used to compare the survival rates of 2 groups. Comparisons of survival rates were performed using a log-rank test. Kaplan-Meier survival curves adjusted by age, gender, HR and cause of HF were constructed, assuming the values of factors were the average of the patients' values. We used multiple regression analysis to find valuables associated with systolic BP (SBP) at re-admission. Stepwise regressions were performed for valuables including age, gender, SBP at steady-state, baPWV, SBP at previous admission because of HF, and HR. Computers (Mebius Muramasa, Sharp, Osaka, Japan) and software (Excel, Microsoft, Dr. SPSS II, SPSS, Chicago, IL, USA) were used for the statistical analyses. A value of P<0.05 was considered significant. 
Results
Patient Characteristics
The etiology of HF was ischemic heart disease in 33, hypertensive heart disease in 20, dilated cardiomyopathy (DCM) in 14, hypertrophic cardiomyopathy in 2 and other causes in 3 patients. The background data are shown in Table 1 . Averaged baPWV data in the HF patients were similar to that of age-matched subjects without HF (data not shown).
Univariate and Multivariate Cox Proportional Hazards Analysis
The mean follow-up period was 14 months. Among the 72 patients, 17 were re-admitted because of exacerbation of HF during the follow-up period. Among the 72 patients, 9 died of cardiac cause. On the basis of ROC curve analysis, an optimal cutoff value of 1,750 cm/s (sensitivity 76.5%, specificity 65.5%, area under the curve 0.703) for baPWV was chosen to predict re-admission by worsening HF. According to this cutoff value, we divided the HF patients into a high-baPWV group or a low-baPWV group.
According to the univariate Cox proportional hazards regression tests for independent predictors of re-admission, the significant covariates retained by the model were highbaPWV (P=0.003), BNP (P=0.029), PP (P=0.02) and SBP (P=0.002) ( Table 2) . Age, gender, cause of HF (ischemic or non-ischemic), HR, PRA, PAC, NE, TC, CRP, creatinine, LVEDd, LVESd, LAd, LVEF, smoking, DM, hypertension and medications did not reach statistical significance. The results of multivariate Cox proportional hazards regression tests showed that baPWV was a significant predictor for clinical outcome, after adjusting for SBP, PP, BNP, age and gender ( Table 3) .
The data for the various parameters measured in the 2 groups of patients divided according to the cutoff point of baPWV (1,750 cm/s) are shown in Table 4 . Age and PP were higher in the high-baPWV group than in the lowbaPWV group (P<0.05). LVEF was similarly reduced in the low-baPWV (54±21%) and high-baPWV (51±15%) groups. Although SBP, diastolic BP and HR can affect the baPWV value, these data were similar between the 2 Figure 1 . (A) Kaplan-Meier curves for event-free survival in the high-brachial-ankle pulse wave velocity (baPWV) and low-baPWV groups. The end-point was re-admission because of exacerbation of heart failure. The patients with high baPWV were significantly more likely than the patients with low baPWV to reach the endpoint (P<0.05 by log-rank test). (B) Kaplan-Meier curves for event-free survival in the high-baPWV and low-baPWV groups. The endpoint was cardiac death. The patients with high baPWV were significantly more likely than the patients with low baPWV to reach the endpoint (P<0.05 by log-rank test).
Figure 2.
Kaplan-Meier curves adjusted by age, gender, heart rate and cause of heart failure for event-free survival in the high-brachial-ankle pulse wave velocity (baPWV) and low-baPWV groups. The endpoint was re-admission because of exacerbation of heart failure. The patients with high baPWV were significantly more likely than the patients with low baPWV to reach the endpoint (P<0.05). groups. The plasma BNP level increased more in the highbaPWV group than in the low-baPWV group (P=0.016). TC, creatinine, PRA and NE concentrations, SBP, medications, smoking rate and percentage of DM cases were similar between groups ( Table 4 ). The CRP level was higher in the high-baPWV group (0.3 mg/dl, interquartile range 0.2-0.8, P<0.05) than in the low-baPWV group (0.1 mg/dl, interquartile range 0.1-0.3), suggesting ongoing chronic inflammation in the high-baPWV group.
Comparison of Prognosis for the High-baPWV and Low-baPWV Groups
Kaplan-Meier survival curves were constructed for the low-and high-baPWV groups. The high-baPWV group had a higher rate of re-admission because of HF than the lowbaPWV group (P<0.05, Figure 1A) , as well as a higher rate of cardiac death (P<0.05, Figure 1B) . One patient who died from a stroke was censored on the day of death. The ages of the low-and high-baPWV groups differed, and therefore Kaplan-Meier curves adjusted by age, gender, HR and cause of HF were also constructed. Both survival curves describe estimated survival probabilities over time assuming the same age (mean age of patients, 68 years), HR (average 72 beats/min), distribution of gender and distribution of cause of HF. High-baPWV was a significant prognostic factor, even when adjusted by age, gender, HR and cause of HF (P<0.05, Figure 2) . The results revealed that the highbaPWV group had a higher event rate than the low-baPWV group after adjusting for age, HR, gender and cause of HF.
BP at Re-Admission and Previous Admission Because of Exacerbation of HF
As shown in Figure 3 , the SBP at re-admission because of exacerbation of HF was higher in the high-baPWV group (174±30 mmHg, P<0.01) than in the low-baPWV group (121±33 mmHg). The SBP at previous admission for HF was also higher in the high-baPWV group (155±23 mmHg, P<0.001) than in the low-baPWV group (134±29 mmHg) (Figure 3) . SBP at previous admission was compared in subgroups divided by cause of HF. BP at previous admission was higher in the high-baPWV group independent of the cause of HF. In the multiple regression analysis, SBP at re-admission was associated with baPWV, even when adjusted for SBP at previous admission. Age, gender, SBP at steady-state, and HR did not reach statistical significance ( Table 5 ). Systolic blood pressure at re-admission for heart failure (HF) is higher in the high-brachial-ankle pulse wave velocity (baPWV) group than in the low-baPWV group (Top left). Systolic blood pressure at previous admission for HF is higher in the high-baPWV group than in the low-baPWV group (Top right). Systolic blood pressure at previous admission is higher in the high-baPWV group whether the cause of HF is ischemic (Bottom left) or non-ischemic (Bottom right). Open bar: low-baPWV group; Solid bar: high-baPWV group. Tables 1,2 .
Circulation Journal Vol.73, April 2009
Discussion
One of the most important findings in the present study is that an elevated baPWV in patients with HF is a risk factor for re-admission because of exacerbation of HF. Furthermore, the Kaplan-Meier survival curves for cardiac death showed higher mortality in the high-baPWV group than in the low-baPWV group. The 1-year re-admission rate was 18.1% and mortality was 8.9%. Our results for the re-admission rate and cardiac death rate of HF patients are similar to those reported from a previous large-scale study in Japan. 17 The second major finding of this study is that SBP at readmission and previous admission because of exacerbation of HF was higher in the high-baPWV group than in the low-baPWV group, although the steady-state hemodynamic factors were similar between the 2 groups (Figure 3) . This finding supports the concept that the BP of patients with a high-baPWV increases easily and that increased BP could induce exacerbation of HF.
PWV, a gauge of arterial stiffness, was reported to be higher in DCM patients than in control subjects, and tended to increase further as the severity, assessed by NYHA class, advanced. 10 Moreover, a recent report indicated that the PWV increased as exercise tolerance decreased in DCM patients. 18 Furthermore, several reports point out that increased aortic stiffness is associated with LV diastolic dysfunction. 19, 20 These previous results demonstrated deleterious effects of elevated arterial stiffness in HF patients and are consistent with our present findings.
However, the pathophysiological mechanism responsible for the relationship between arterial stiffness and re-admission for HF remains unclear. Therefore, we focused on the mechanism of onset of acute HF from the viewpoint of arterial stiffness. Our first suggested mechanism is that elevated SBP at admission induces LV dysfunction. The BP at the time of admission for acute HF was higher in the highbaPWV group compared with the low-baPWV group, despite similar steady-state BP. We speculate that the BP of the high-baPWV group rises more easily. In our data, the BP at re-admission was associated with a steady-state baPWV value, even when adjusted for SBP at previous admission for HF. Therefore, HF patients with higher baPWV have a potential risk of experiencing higher SBP at re-admission because of HF. Milo-Cotter et al reported that BP is elevated substantially at the onset of acute HF. 21 If HF patients with increased baPWV have a sudden increase in SBP for any reason, they would easily develop acute HF with an impaired systolic loading sequence produced by the rapid traveling of the reflection wave in the stiffer arterial tree. The impaired loading sequence to the LV provokes deterioration of LV relaxation. Therefore, elevated BP can exacerbate systolic and diastolic LV function, which induces acute pulmonary edema in HF patients. 22 Moreover, a depressed Windkessel effect can itself increase afterload. In this situation, elevated afterload can induce afterload mismatch, which induces diastolic LV dysfunction and pulmonary edema at admission. 23 The second possible explanation is that patients with increased arterial stiffness have increased LV stiffness. Our results show that the steady-state plasma BNP level was higher in the high-baPWV group than in the low-baPWV group, despite a similar LVEF between groups. An elevated BNP level suggests the presence of increased LV stiffness. A previous study reported that combined ventricular and arterial stiffening is one of the mechanisms that induce acute HF in elderly patients. 24 Others have reported that increased arterial stiffness is associated with impaired LV relaxation. 19, [25] [26] [27] The third possibility is impairment of LV function attributable to an early reflection wave in the high-baPWV group. 28 Although we did not measure the augmentation index, an early reflection wave may have increased the LV systolic load and reduced the systolic ejection duration and stroke volume in the high-baPWV group. Because a LV with elevated arterial stiffness has potentially impaired LV systolic and/or diastolic function, a sudden increase in SBP in the high-baPWV group could induce acute LV diastolic dysfunction with elevated LV filling pressure and pulmonary edema. In our study, the higher BNP level under steady-state conditions and higher SBP at admission in the high-baPWV group support this scenario. However, non-HF patients with high baPWV did not have an episode of admission because of HF (data not shown). Therefore, merely having a high baPWV is not enough to induce HF. The association of high baPWV and an impaired LV is the risk for re-admission because of HF. A combination of these and other precipitating factors may have induced acute pulmonary edema at re-admission in the high-baPWV group.
We found that the baPWV was an independent prognostic factor in our study sample. Previous reports have shown that the baPWV is affected by age, HR and SBP. [29] [30] [31] [32] Although the SBP and HR were similar between the groups in the present study, the high-baPWV group were older than the low-baPWV group. However, the results of the univariate and multivariate Cox proportional hazards tests showed that age was not a significant prognostic factor. The multivariate Cox proportional hazards test showed that baPWV was a significant prognostic factor, even when adjusted by age, gender, BP, PP and BNP. Moreover, Kaplan-Meier analysis adjusted by age, gender, HR and cause of HF also revealed that there was a higher rate of readmission in the high-baPWV group.
We could not identify the mechanism leading to cardiac death in the high-baPWV group in the current study, and there may have been a variety of mechanisms. Because cardiac death includes not only death by pump failure but also unexpected sudden death because of arrhythmia, which cannot be completely predicted by hemodynamics, this uncertainty regarding the mechanism stems from the multiple causes of death among patients with HF. Further investigations are necessary to determine the reasons for cardiac death.
We found that the high-baPWV group had a higher serum CRP level than the low-baPWV group, which may be a result of the depressed LV function. 33, 34 Another explanation is that an elevated CRP level (0.1-1.0 mg/dl) is an index of atherosclerosis accompanied by elevated arterial stiffness. 35, 36 Although atherosclerosis is primarily an intimal disease of arteries, and arteriosclerosis is primarily a medial disease, 37 atherosclerosis is reported to accompany elevated arterial stiffness. [38] [39] [40] [41] [42] In our data, because LV systolic function was relatively preserved at similar levels in both the high-and low-baPWV groups, it is possible that the increased CRP level in the high-baPWV group reflects chronic ongoing inflammation caused by atherosclerosis of the arterial tree. Our interpretation of the present data is that the high-baPWV group had more advanced ongoing atherosclerosis and arteriosclerosis in their systemic arterial trees. Because SBP or LVEF was similar between highbaPWV group and low-baPWV group, ongoing anatomical changes may affect mainly arterial stiffness measured by baPWV. This ongoing inflammation in atherosclerosis could be a target for treatment. In our data, the LV dimensions were smaller in the high-baPWV group compared with the low-baPWV group. One interpretation is that the high-baPWV group has a higher afterload and lower preload compared with the low-baPWV group. Another interpretation is that the high-baPWV group may have higher effective arterial elastance (Ea) and lower stroke volume than the low-baPWV group. In this situation, because both the LVEF and SBP were similar between groups, the LV dimensions in the high-baPWV group would be smaller than those of the low-baPWV group. 24, 43, 44 Further hemodynamic studies are required to clarify this point.
The impact of this study is that the BP of HF patients with high arterial stiffness should be controlled strictly. Moreover, increased arterial stiffness may represent a new target for HF management. Several medications (ie, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, statins 45 ) are known to decrease arterial stiffness. 46 Further studies are required to elucidate the effects of these medications on arterial stiffness in HF patients by measuring the baPWV.
In conclusion, elevated baPWV is a risk factor for readmission for exacerbation of HF and for cardiac death in HF patients. One mechanism for the exacerbation of HF at re-admission in patients with high baPWV may be elevated afterload superimposed on impaired LV function. The results of this study suggest that arterial stiffness may be a target for therapeutic management of patients with HF.
